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Immunophilins are a family of receptors for immunosuppressive drugs like cyclo-
sporin A, FK506, rapamycin and their non-immunosuppressive analogues, which 
are collectively referred to as immunophilin ligands. The present study aimed to 
review neuroprotective and neuroregenerative actions of immunophilin ligands 
on peripheral nerve injuries. The special emphasis was given to well-known im-
munosuppressive drug FK506. Its historical background, administration routes, 
dosages, neuroregenerative, neuroprotective actions, therapeutic time window 
in administration, action mechanism and side effects of FK506 were reviewed. 
(Folia Morphol 2015; 74, 4: 407–413)
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INTRODUCTION
Immunophilins are a family of receptors for im-
munosuppressive drugs like cyclosporin A, FK506, 
rapamycin and their non-immunosuppressive analo-
gues, which are collectively referred to as “immuno-
philin ligands” [3]. In contrast to neurotrophins (e.g., 
nerve growth factor), immunophilin ligands readily 
cross the blood-brain barrier, being orally effective in 
a variety of animal models of ischaemia, traumatic 
injuries and human neurodegenerative disorders [27]. 
FK506 and rapamycin show their effects via binding 
to a class of immunophilin called FK506-binding pro-
teins (FKBP), designated according to their molecular 
weight: FKBP12, 25, 52, etc. FKBP52 is also known 
as FKBP59 or heat shock protein 56 and is a compo-
nent of steroid receptor complexes [2]. Cyclosporin A 
shows its effects via binding to cyclophilin [72].
CYCLOSPORIN A
Cyclosporin A is a neutral lipophilic cyclic undeca-
peptide, of molecular weight 1202.6, obtained from the 
fermentation broth of two fungi, Trichoderma polyspo-
rum and Cylindrocarpon lucidum [45]. Its immunosu-
ppressive activity was first reported by Borel et al. [5] 
at Sandoz Laboratories in 1972. Discovery of the cyclo-
sporin A has revolutionised transplantation medicine in 
which there is a need for immunosuppressive therapy.
Generally, cyclosporin A has similar immune-
-suppressing characteristics to FK506, but FK506 
delivers a more potent effect with equal volumes of 
drug. Cyclosporin A binds to a class of immunophilins 
called cyclophilins [72]. Cyclophilin–cyclosporin A 
complex can associate with calcineurin [48]. Calci-
neurin (also known as PP-2B), is known as a calcium 
and calmodulin-dependent protein serine/threonine 
phosphatase. The role of calcineurin in T cell receptor 
signalling was identified as the common target for 
cyclosporin A and FK506 [71]. Calcineurin consists of 
two subunits, a catalytic subunit calcineurin A, and 
a regulatory subunit calcineurin B [55].
RAPAMYCIN
Rapamycin is another immunosuppressant drug 
structurally related to FK506 and appears to act upon 
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a similar step that exists in distinct signalling pathways 
associated with growth factor receptors [18]. Simi-
larly, Myckatyn et al. [56] reported that animals tre-
ated with FK506 and rapamycin had significantly less 
immune cell proliferation within their severed nerve 
than control animals, with axon regeneration being 
superior in FK506 than rapamycin-treated animals. 
Rapamycin has a structural similarity with FK506 
but does not block cytokine transcription at the early 
stages of T-cell activation. Rapamycin inhibits proli-
feration of T cells in response to growth-promoting 
cytokines like interleukin-2 at the G1- to S-phase 
progression [36]. FK506 and rapamycin show their 
effects via binding to a class of immunophilin called 
the FK506-binding protein-FKBP12 and the FKBP-
-rapamycin-associated protein [12]. Rapamycin binds 
to FKBP and the complex binds to rapamycin and 
FKBP-12 target [63]. FKBP-12 target affects protein 
translation by phosphorylating p70-S6 kinase, which 
phosphorylates the ribosomal S6 protein, and 4E-BP1, 
a repressor of protein translation initiation. Immu-
nophilin levels are much higher in the brain than in 
immune tissues, and levels of FKBP12 increase in re-




FK506 (its genetic name is Tacrolimus, Prograf™) 
was first discovered in 1984 by Fujisawa Pharma-
ceutical Company while screening for antibacterial 
activity of a multitude of compounds [43]. It was 
isolated from Streptomyces tsukabaensis, a bacterium 
found in the soil near Tsukuba, Japan [42, 43]. For 
this reason, the name of the drug is derived from the 
phrase of Tsukuba, the name of the mountain from 
which the soil sample was extracted; macrolide, its 
chemical class; and immune suppressant, its primary 
activity in humans [57]. 
Action mechanism of FK506
In experimental studies, it has been documented 
that FK506 enhances the rate of axonal regenera-
tion after peripheral nerve injury [29, 30, 39, 76, 77] 
and reduces post-occlusional disturbances of the 
central nervous system [1, 17, 58, 66]. It would 
not be expected that an immunosuppressant drug 
(FK506) would alter axonal regeneration since Walle-
rian degeneration is not an immune-mediated event. 
Gillon et al. [25] studied the ability of peripheral 
nerve allografts (from Dark-Agouti rats) to support 
regeneration of adult rat retinal ganglion cell axons 
in immunosuppressed host Lewis rats and found 
that systemic administration of the cyclosporin A 
or FK506 significantly reduced cellular infiltration 
into peripheral nerve allografts and resulted in more 
extensive axonal regeneration [25]. Fansa et al. [20] 
reported a decrease in myelin debris in autologous 
nerve grafts by administration of 0.6 mg/kg FK506. 
Furthermore, even if a reduction in macrophage in-
filtration occurs following FK506 administration [9], 
such an alteration would be expected to impair nerve 
regeneration by delaying the removal of debris from 
the distal stump [11, 49]. 
It is well documented that FK506 activity is media-
ted by FKBP (FK506 binding protein). Lyons et al. [51] 
reported significant increase in FKBP12 levels in facial 
or sciatic nerve nuclei after crush injury. Synder and 
Sabatini [67] also showed levels for FKBP-12 mRNA 
increased significantly in motor neurons following 
peripheral nerve axotomy. Presence of high levels of 
FKBP corresponds with the presence of high levels 
calcineurin [51, 67]. The influence of FK506 on axon 
regeneration is predominantly through the binding to 
FKBP-12, which activates GAP-43 and the transforming 
growth factor (TGFb1) pathway [21, 31]. The FK506-
-FKBP complex further binds to calcineurin, preventing 
the dephosphorylation of the nuclear factor of activa-
ted T cells and blocking the cascade of cytokine gene 
transcription. Calcineurin has the ability to dephosp-
horylate a broad range of proteins [54]. One of the 
major targets for calcineurin in neurons is GAP-43. Both 
GAP-43 and neuronal phosphates are concentrated in 
growth cones of the proximal stump of the lesioned 
nerve, where they are believed to play an important 
role in nerve regeneration [64]. In an elegant study, 
Gold et al. [32] demonstrated that non-FKBP-12 ligand 
(V-13.670) accelerates functional recovery and nerve 
regeneration in the rat sciatic nerve crush model.
Neuroregenerative actions of FK506 
FK506 is the first agent in which systemic expo-
sures have been demonstrated to increase axonal 
regeneration rate [30]. Continuous infusion of insulin 
like growth factor I, cyclosporin A, adenocorticotro-
pic hormone (ACTH) analogue Org 2766 directly to 
the lesion site have been shown to increase axonal 
regeneration [19, 26, 40]. Although systemic admi-
nistration of the ACTH analogue Org 2766 increase 
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recovery of function, rate determinations have not 
been reported [15, 68] Additionally, FK506 is not 
structurally related to any known growth-promoting 
factor and it is therefore likely to accelerate regene-
ration via a novel mechanism [30].
Despite documented neurotoxicity with high do-
sages, both cyclosporin A and FK506 have had no 
deleterious effect on nerve regeneration of nerve 
allografts. Gold et al. [30] noted an increased rate of 
nerve regeneration after FK506 treatment in axonot-
mesis model of the sciatic nerve. Additionally, their 
group also studied the efficacy of delayed or discon-
tinuous FK506 administration on axonal regenera-
tion and found that both delayed and discontinuous 
administration were less effective than continuous 
administration [29]. 
FK506 treatment has been document in facial [16], 
sciatic [30, 64, 73], vagus [33] and obturator nerve 
models [79]. FK506 enhances collateral sprouting 
of peripheral nerve fibres [73]. Sulaiman et al. [70] 
studied whether FK506 is effective after chronic nerve 
injuries (chronic axotomy, chronic Schwann cell dener-
vation). For chronic axotomy, injured tibial nerve was 
sutured to a freshly cut common peroneal nerve after 
2 months delay. For chronic denervation, injured distal 
common peroneal nerve was sutured to a freshly cut 
tibial nerve after 2 months delay. In contrast to effect 
of FK506 in chronic axotomy model, FK506 did not 
improve the reduced capacity of Schwann cells to 
support axonal regeneration in chronic denervation 
model. Sulaiman et al. [70] suggest that FK506 acts 
directly on the neuron (as opposed to the denervated 
distal nerve stump) to accelerate and promote axonal 
regeneration of neurons whose regenerative capacity 
is significantly reduced by chronic axotomy. 
Scar formation is another important issue for pe-
ripheral nerve regeneration. Traditionally, surgeons 
attempt to control collagen scar formation by close 
approximation of corresponding fascicles of the pro-
ximal to distal stumps [23, 37]. Excessive collagen 
formation can create a mechanical barrier to axonal 
regeneration, and the resulting scar formation can 
hinder axonal regrowth [41, 44, 53]. Que et al. [62] 
studied the effect of FK506 in reducing scar forma-
tion by inducing fibroblast apoptosis after sciatic 
nerve injury in rats. They suggest that FK506-induced 
fibroblast apoptosis contributes to the suppression 
of fibroblast proliferation and then results in the re-
duction of scar formation in injured nerve, and that 
c-Jun N-terminal kinase (JNK) and extracellular-signal-
-regulated kinase (ERK) are involved in FK506-induced 
fibroblast apoptosis.
Despite effect of FK506 on traumatic nerve inju-
ries has been documented in literature, few studies 
reported by our group on vascular injuries of the pe-
ripheral nerve. In a previous study [75], we reported 
a beneficial effect of the FK506 on subperineurial 
degeneration and demyelination of the nerve fibres 
in the watershed zones of the sciatic nerve after 
stripping of the epineurial vessels. Earlier studies 
suggested that sufficient oxygen could diffuse into 
peripheral nerve from its environment to delay ischa-
emic conduction failure and to prevent fibre dege-
neration in ischaemic nerves [17, 29, 30]. In another 
study [35] we also demonstrated that reduction of 
the per cent of watershed areas in the subperineurial 
area was not affected from FK506 administration. This 
result supports the evidence of the neuroprotective 
effects of the FK506. This effect may be modulated 
by reducing the scar formation as reported recently 
by Que et al. [62] or by changing the blood flow 
through collaterals of the vasa nervorum. 
Neuroprotective actions of FK506
Knowledge on mechanism of action of immu-
nophilin ligands may shed light on neuroprotective 
actions in neurons. In several animal models simu-
lating Parkinson’s disease, dementia and surgical 
damage, it has been reported that immunophilin 
ligands induces sprouting by acting as neurotrophic 
agents and preventing nerve damage [61]. FKBP12 
might be protective due to its action of binding to and 
stabilising inositol trisphosphate (IP3) and ryanodine 
calcium channels [8, 10], since an increase in intra-
cellular calcium levels has been linked to neuronal 
death [2]. 
Trauma-induced neurological losses are the main 
challenge for physicians since trauma leads to the 
death of some perikarya located in the central nervous 
system. Attempts to reduce the secondary changes 
in the neurons will reduce the functional loss of the 
peripheral nerve. Thus, the administration of the im-
munosuppressants in a therapeutic time after trauma 
will result to maintaining the neurons viability and 
allowing to regenerate and re-establish connections 
to their original target [72]. Although protection 
against focal cerebral ischaemia has been reported, 
even when FK506 administered even up to 60 min po-
stocclusion of the middle cerebral artery [1, 6, 58, 80], 
neurite outgrowth rat dorsal root ganglia has been 
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documented in the literature [50]. Its neuroprotecti-
ve effect on primary cortical cultures has also been 
demonstrated [14].
Therapeutic time window in administration of FK506 
In the clinical routine an immediate reconstruc-
tion of the lesioned nerve is seldom possible since 
clinicians tend to wait prior to making their diagnosis 
and plans for treatment [72]. In contrast to typical 
animal models for nerve regeneration studies, mostly 
there is a certain denervation time of the affected 
nerve between lesion and reconstruction. Therefore, 
it is important to know the optimal therapeutic time 
window of effectiveness of FK506 following nerve 
trauma. Focal ischaemia in which FK506 effective-
ness is dependent on its dose and therapeutic time 
window is well studied in experimental studies [1, 24]. 
Chunasuwankul et al. [13] demonstrated that 
prolonging FK506 treatment (from 2 months to 
3 months treatment) following an acute nerve cut 
did not increase the recovery of function. Contrary 
to this effect, when FK506 is administered 2 months 
after nerve transection rate of axon regeneration 
was doubled. This result may be considered in line 
of when it is administered to an acutely damaged 
peripheral nerve [70]. It has been reported that 
5 mg/kg/day subcutaneous administration of FK506 
is equally as effective when given discontinuously, 
starting immediately following nerve section (days 
0–8 and 10–17), or with a delay (days 9–17), with con-
tinuous administration starting immediately being 
most effective [76]. Brenner et al. [7] studied delay 
administration of FK506 and reported the greatest 
influence of FK506 when it was administrated imme-
diately following the lesion. Delaying for the nerve 
repair and for the administration of FK506 (even 
by 7 days), or immediate surgery with delayed ad-
ministration of FK506 leaded to less extensive axon 
regeneration and fewer motor neurons extending ax-
ons [7]. Okajima et al. [60] reported that short-term 
administration (12 weeks) of FK506 was sufficient 
to lead to good nerve regeneration in peripheral 
nerve allografts.
Administration routes and dosages of FK506
A broad range of dosages (0.3–10 mg/kg) of the 
FK506 for peripheral nerve regeneration has been 
reported in the literature [4, 20, 22, 30, 31, 39, 46, 
52, 77]. It can be thought that the wide range of these 
dosages may be due to the administration route of 
the FK506. It has been reported that the most effec-
tive neuroprotective dose of FK506 is 1 mg/kg [24, 
58, 80], which corresponds to immunosuppressive 
dose in humans [66].
Wang et al. [77] reported a dose dependent fa-
shion of FK506 treatment on nerve regeneration. 
They studied the effect of 2, 5, and 10 mg/kg doses 
of FK506 on recovery of function. They reported that 
recovery was maximally accelerated with daily admi-
nistration of 5 mg/kg dose. 10 mg/kg dose of FK506 
was observed to be less effective. Fansa et al. [20] also 
studied the effect of 2 dosages (0.3, 0.6 mg/kg s.c.) 
of FK506 on peripheral nerve regeneration following 
nerve grafting and reported significantly higher axon 
count in both groups administrated 2 dosages of the 
FK506. But there is no consensus about the optimal 
dose of the FK506 to achieve the best regeneration 
rate. Additionally, the dosages reported in the litera-
ture are seemed to be very high dosages [64].
Although subcutaneous, oral, intramuscular 
FK506 administrations have been frequently reported, 
to our knowledge, there is only 1 study investigating 
the effect of intrathecal FK506 administration on 
axonal regeneration [64]. The lowest dose reported in 
the literature was studied by our research group. We 
administered 0.05 mg/kg/day dose of FK506 intrathe-
cally and studied the beneficial effect of FK506 after 
sciatic nerve injury. This beneficial effect was confir-
med by myelin loss, myelin degeneration, functional 
and sensory function. Since liver transplant patients 
receive approximately same dose, we used this dose 
to obtain lesser immunosuppression, neurotoxicity. 
We think that intrathecal administration of the FK506 
should be kept in mind to decrease side effects of the 
FK506 during treatment of the nerve injury. 
One of the other administration routes is loading 
the FK506 to semi-permeable wall of chitosan guide 
(647 µg/g). FK506 was dispersed in chitosan guide 
wall during fabrication of the chitosan guide. It was 
reported that FK506 releasing from biodegradable 
chitosan guide provided better nerve regenerative 
response than the guide with no FK506 [47]. 
Side effects of FK506
In addition to its ability to suppress the immune 
system cells (T-cell activity) FK506 has a number of 
non-immune effects [17, 34, 59, 65, 74, 78]. Although 
an increased rate of axonal regeneration has been 
noted in various rodent models [30, 51], neurological 
and other side effects, such as metabolic, cosmetic, 
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and neuropsychiatric complications resulted from 
immunosuppressant therapy with FK506 have also 
been reported in the central and peripheral nervous 
system [72]. New immunosuppressive agents, such 
as mycophenolate mofetil and sirolimus, have similar 
side effects. The neuroregenerative property of the 
immunophilin ligands does not involve calcineurin 
inhibition (it is essential for immunosuppression). This 
pathway is important since most of the limiting side 
effects produced by these drugs arise via calcineurin 
inhibition [27].
One of the more serious complications of FK506 
treatment in animal models is the development of 
diabetes mellitus [72]. However, up to 240 days ad-
ministration of FK506, the increased glucose levels 
are not chronic, and eventually return to normal level, 
making FK506 treatment effects on glycaemia only 
a time-related side effect [60]. One of the mechanism 
at which FK506 appears to induce neurological side 
effects is production of reactive oxygen species and 
a decreased the levels of antioxidant enzymes [38]. It 
is proposed to inhibit these side effects by co-admi-
nistration of antioxidants with FK506 administration. 
Although there are some choices to decrease the side 
effects cyclosporine and FK506-based immunosu-
ppressive treatments induce additional side effects, 
such as metabolic, cosmetic, and neuropsychiatric, 
which still raise concern about their use [69]. 
In a previous study we administered the FK506 
intrathecally (0.05 mg/kg/day), the lowest dose repor-
ted in the literature for treatment of the sciatic nerve 
injury, and found no side effects in the FK506-treated 
animals. Thus, side effects may be diminished by using 
alternative administration route. 
NONIMMUNOSUPPRESSANT  
FK506 ANALOGS
Three non-immunosuppressant FK506 analogues 
such as V-13.450, V-13.629, and V-13.670 have also 
been described by Gold et al. [28]. They are equi-
potent to FKBP-12 ligands (FK506, V-10.367, and 
V-13.449) for increasing neurite elongation in SH-SY5Y 
cells in hippocampal neurons from FKBP-12 knockout 
mice [28]. 
CONCLUSIONS AND FUTURE  
PERSPECTIVE
Novel non-immunosuppressant ligands for FKBPs 
seemed an alternative for returning the recovery of 
function after peripheral nerve injury. Although FK506 
is used extensively for its immunosuppressive actions 
because of its limited number of side effects, espe-
cially when used in adults, new compounds must be 
further studied for their potential benefits in enhan-
cing axon regeneration and neurological recovery 
following diseases of both peripheral and central 
nervous system.
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